Search alternatives:
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
wt decrease » _ decrease (Expand Search), nn decrease (Expand Search), awd decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a non » _ non (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
wt decrease » _ decrease (Expand Search), nn decrease (Expand Search), awd decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a non » _ non (Expand Search)
-
1501
Image2_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF
Published 2022“…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
-
1502
Table2_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.DOCX
Published 2022“…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
-
1503
Image11_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF
Published 2022“…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
-
1504
Image3_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF
Published 2022“…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
-
1505
Image13_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF
Published 2022“…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
-
1506
Image14_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF
Published 2022“…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
-
1507
Image1_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF
Published 2022“…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
-
1508
Severe decreases of TECs and impaired TEC expansion in the absence of mTORC1/Raptor.
Published 2016“…The gating strategy is shown in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1002370#pbio.1002370.s003" target="_blank">S2 Fig</a>. …”
-
1509
-
1510
-
1511
Table2_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.docx
Published 2022“…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
-
1512
Table1_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.xlsx
Published 2022“…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
-
1513
Table1_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.xlsx
Published 2022“…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
-
1514
Table2_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.docx
Published 2022“…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
-
1515
Image 7_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif
Published 2025“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
-
1516
Image 6_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif
Published 2025“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
-
1517
Image 3_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif
Published 2025“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
-
1518
Image 1_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif
Published 2025“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
-
1519
Image 2_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif
Published 2025“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
-
1520
Image 4_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif
Published 2025“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”